A recent study in JAMA American highlights that even modest weight loss can result in significant cost savings. Researchers at Emory University analyzed data from over 17,000 individuals, some of whom had private insurance others had Medicare. The findings are eye-opening: Individuals with private insurance reduced their annual healthcare spending by 8% with 5% weight loss, while those who lost 25% saw a 24% reduction. Similarly, those on Medicare saw cost savings of 7% with 5% weight loss and 31% with 25% weight loss. Research findings like this adds to the growing body of clinical evidence showing that treating obesity not only improves comorbidities but also leads to meaningful patient outcomes and substantial healthcare savings. Are you an employer seeking a proven, science-based obesity solution to support sustainable weight loss, better health outcomes, while controlling cost ? Form Health can help. Our team of obesity specialists partners with patients to achieve their weight and health goals while addressing the high costs of obesity and cardiometabolic conditions. Email us at employers@formhealth.co to learn more.
Form Health
Hospitals and Health Care
Boston, Massachusetts 4,905 followers
Form Health is the national leader in science-based obesity care.
About us
Form Health is the national leader in science-based obesity care. Our clinical care model consists of one-on-one, personalized care from a dedicated ABOM-certified physician and a CSOWM-certified Registered Dietitian, who develop individualized treatment plans that address behavioral health, nutrition, physical activity, and include a prescription for FDA-approved medication, if appropriate. Form Health keeps safety, efficacy, and outcomes at the forefront as we incorporate the latest research and science into our approach. This means we’re always innovating, constantly getting smarter about the science of obesity care, relentlessly focusing on exceptional results, and calling out harmful practices that hold back progress. The result is life-changing outcomes for our patients and meaningful ROI for our enterprise partners. Form Health is in-network with national health plans. Learn more at formhealth.co.
- Website
-
http://formhealth.co
External link for Form Health
- Industry
- Hospitals and Health Care
- Company size
- 51-200 employees
- Headquarters
- Boston, Massachusetts
- Type
- Privately Held
- Founded
- 2019
Locations
-
Primary
Get directions
109 State St
5th Floore
Boston, Massachusetts 02109, US
Employees at Form Health
Updates
-
Form Health Principal Engineer Daniel Zajic shares his favorite thing about working at Form Health is the culture of always putting patients first. Are you excited about making a difference in patient lives and working with a team who is dedicated to transforming healthcare? Join our team! Explore our job opportunities: https://lnkd.in/dZUp2V6p
-
-
Form Health is proud to sponsor the 2024 Purchaser Business Group on Health (PBGH) Annual Summit. Will you be in Austin for this year's event? Be sure to connect with Tom Kahl to learn how we help organizations provide an evidence-based obesity benefit that delivers sustained weight loss and improved cardiometabolic health while managing costs. Not attending, but want to learn more? Contact us at employers@formhealth.co to discuss how we can help your organization meet its goals.
-
-
Today's Innovation Roundtable, A World 50 Group Community Pharmacy Deep Dive was a great event. Dr. Melani Cheers, Corporate Medical Director at U.S. Steel, and Florencia Halperin, Chief Medical Officer at Form Health, had a great discussion on GLP-1s and obesity medicine while providing insights about selecting and implementing a clinical obesity solution. Evan Richardson, Form Health CEO, moderated the lively conversation which dove into understanding the risks of compounded medications, navigating challenges with PBMs when introducing an obesity COE, and leveraging clinical data to drive sustainable patient outcomes and ROI. Looking for an evidence-based obesity solution that delivers life changing weight loss and health improvements while maximizing ROI? Contact employers@formhealth.co to learn more.
Our EHIR Winter Deep Dive in Boston is officially underway! From thought-provoking discussions to meaningful connections, this event is already a resounding success. A heartfelt thank you to everyone attending, sharing their insights, and contributing to making this gathering so impactful. Your commitment to driving meaningful change in healthcare inspires us every day. A special shoutout to our amazing innovator community here with us: SmithRx, Omada Health, Navitus Health Solutions, AffirmedRx, a Public Benefit Corporation, VIVIO, a Public Benefit Corporation, Form Health, Noom
-
-
Chief Medical Officer, Florencia Halperin, has consistently shared concerns about the safety of compounded GLP-1 and GLP-1/GIP receptor agonists. She outlines additional reasons for concern that were detailed in the paper recently published by American Diabetes Association. After reading, she concludes, "Compounded anti-obesity medications are just not a safe option for patients." At Form Health, we are committed to providing safe and effective science-based obesity care. That’s why we only prescribe FDA-approved medications, as clinically appropriate. Let us show how we can help your organization offer evidence-based obesity care that transforms lives, delivers ROI, and always prioritizes patient safety. Contact us at employers@formhealth.co to learn more.
The American Diabetes Association published a paper this week on compounded GLP-1 and GLP-1/GIP receptor agonists. I have written about this before, but I learned so many crucial tidbits that I need to share. They come out very explicitly saying "Compounded GLP-1 RA and Dual GIP/GLP-1 RA Therapies Are Not Identical to the FDAApproved Products". ✅ It turns out that to compound a copy of an FDA-approved product one needs to follow a U.S. Pharmacopoeia (USP) monograph to ensure product quality, including its strength, purity, and performance. Because semaglutide or tirzepatide have not been around long enough, USP monographs are not even available! The compounders don't have the standard protocols. Yikes. ✅ When compounded products incorporate additional ingredients (vitamin B12 or B6), that inherently changes the composition. Compounded products are not subject to bioequivalence testing like FDA-approved meds, so we don't know the impact of added ingredients on efficacy, and safety. Not been tested! And the salt forms of semaglutide are definitely not chemically identical to the non-salt form, which could also result in clinically meaningful differences in the effectiveness and safety. ✅ There is an entire section on the reports of dosing errors and adverse events that have already been reported. All of the above have nothing to do with 503B vs 503A pharmacies. Not that I needed more convincing, but compounded anti-obesity medications are just not a safe option for patients. We need to continue to highlight the science, because the consumer market is exploiting the commercial opportunities at the expense of people with a chronic metabolic disease, and when you get down into the details, this is even more frightening!
Compounded GLP 1 and Dual GIP/GLP 1 Receptor Agonists: A Statement from the American Diabetes Association
diabetesjournals.org
-
Attending the DFW BUSINESS GROUP ON HEALTH 20th Annual Benefits Forum in Dallas next week? Stop by to say hello to Tom Kahl and learn how Form Health is helping organizations provide science-based obesity care that improves cardiometabolic health while controlling costs. We'd love to share how we can help your members achieve life-changing weight loss and deliver ROI. Not attending but want to learn more? Email us at employers@formhealth.co.
-
-
Mercer's Annual Health Benefits Survey reveals that more employers are covering GLP-1s for obesity. This trend reflects increasing confidence that these medications can effectively treat obesity and reduce the downstream medical costs of related cardiometabolic conditions. However, cost concerns remain. To maximize the impact of investment in GLP-1s, it's critical they are paired with specialized clinical care to ensure safety and efficacy. Form Health helps employers provide a science-based obesity benefit that delivers patient outcomes and financial results. Our ABOM physicians and CSOWM Registered Dietitians provide personalized care with comprehensive treatment plans that address behavioral health, nutrition, physical activity, and may include a prescription for FDA-approved medication, if appropriate. Let us help your organization implement a comprehensive obesity care solution that transforms lives and controls costs by ensuring responsible use of GLP-1s. Contact employers@formhealth.co to learn more. Mercer Health Plan report-
National Survey of Employer-Sponsored Health Plans
mercer.com
-
Director of Clinical Nutrition Julia Axelbaum, RD, CSOWM shares key takeaways from a recent publication in Journal of the Academy of Nutrition and Dietetics: Registered Dietitians play a pivotal role in optimizing obesity care outcomes, particularly when GLP-1s are part of the treatment plan. At Form Health, all patients work with a CSWOM Registered Dietitian to provide medical nutrition therapy as part of comprehensive obesity care that also addresses behavioral health and physical activity along with FDA-approved medication, if approrpriate. Working closely with medical experts like an ABOM physician and CSOWM RD ensures treatment plans are safe, adaptable, and effective for sustained success. Is your company seeking a partner that can deliver science-based obesity care that helps patients achieve sustainable weight loss and improved health while controlling cost? Contact us at employers@formhealth.co to learn how we can help.
🚨 Excited to share an important new publication in the Journal of the Academy of Nutrition and Dietetics "Incretin-Based Therapies and Lifestyle Interventions: The Evolving Role of RDNs in Obesity Care with Lifestyle and Medication." This is the first paper to highlight the critical role of Registered Dietitians in obesity care, particularly with incretin-based therapies like GLP-1 medications. I had the privilege of serving as a peer reviewer for this paper and learned so much from the authors, who are incredible leaders in this field and strong advocates for RDs. Linda Gigliotti, MS, RDN, CDCES, FAND Hope Warshaw Colleen Dawkins Caroline Susie RDN, LD Robert Kushner, MD Alison Evert Mary Rozga Deepa Handu Julie Schwartz @Savitha Subramanian Key takeaways: 👉 Obesity care is most effective with an interprofessional team—RDs play a pivotal role in optimizing outcomes. 👉 RDs support lifestyle changes that enhance weight loss, reduce medication side effects, and promote long-term health. 👉 Advocacy for access to RD-provided medical nutrition therapy (MNT) is vital for comprehensive obesity care. Read the full paper here: https://lnkd.in/esVkF3Ua
Incretin-Based Therapies and Lifestyle Interventions: The Evolving Role of Registered Dietitian Nutritionists in Obesity Care
jandonline.org
-
New research published in the NEJM adds to the growing evidence that tirzepatide can significantly improve cardiometabolic health. The latest findings show that tirzepatide reduced the risk of death and worsening heart failure compared to placebo, in a population of individuals living with obesity and advanced heart failure. These results reinforce that anti-obesity medications like tirzepatide can improve health outcomes, even in very sick individuals. Addressing obesity, a root cause of many cardiometabolic conditions can also help control the long-term costs of other chronic diseases. Are you an employer seeking a partner to provide an science-based obesity solution that helps members achieve sustained weight loss and improved health while controlling costs? Contact us at employers@formhealth.co to learn how we can help.
We are on a roll this week with new science on the effects of novel anti-obesity medications and the impact on cardiometabolic disease! Another randomized controlled trial published in the NEJM. Hundreds of patients with obesity and advanced heart failure were studies - this is a very sick population of patients. Treatment with tirzepatide (the dual GLP-1 and GIP receptor agonist) compared to placebo led to a lower risk of the composite end point - death from cardiovascular causes, and worsening heart failure. The clinical health status and function improved in those who got drug as well. This adds to the list of ways in which this class of drugs helps even the sickest people in the population get healthier. And it ties in to making the economic case for treating obesity, as the list is growing of all the health costs that are avoided downstream when we prevent and treat cardiometabolic disease progression.
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity | NEJM
nejm.org
-
GLP-1 medications offer myriad benefits and have changed how many people view and treat obesity. Dr. Sanjay Gupta explains how these medications work, how they help with weight loss, and why they’re not meant to be a stand-alone treatment. GLP-1 medications should always be used along with lifestyle intervention and under clinical supervision for safety and efficacy. At Form Health, every patient partners with a dedicated Care Team which includes an ABOM physician and a speicalized Registered Dietitian. Together, they create a personalized plan that addresses behavioral health, nutrition, physical activity, and may include a prescription for FDA-approved medication, when appropriate. This comprehensive approach helps patients achieve their weight loss and health goals. Working closely with medical experts ensures treatment plans are safe, adaptable, and effective for sustained success. Are you looking for a partner to deliver an obesity solution that leverages the latest science for sustainable weight loss and improved health, all while controlling costs? Contact us at employers@formhealth.co to learn how we can help.https://https://lnkd.in/e-vwRZDP
-